Back to top
more

NeoGenomics (NEO)

(Real Time Quote from BATS)

$13.28 USD

13.28
118,915

-0.43 (-3.14%)

Updated Jul 9, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks.com featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products

First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Best Breakout Stocks to Invest in for Superlative Returns

First Watch Restaurant Group (FWRG), NeoGenomics (NEO), and Universal Stainless & Alloy Products (USAP) have been selected as the breakout stocks for today.

NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 35.71% and 8.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights Portillo's, NeoGenomics and Wingstop

Portillo's, NeoGenomics and Wingstop have been highlighted in this Screen of The Week article.

Sanghamitra Saha headshot

3 Top Stocks Likely to Exceed Estimates This Earnings Season

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Portillo's Inc. (PTLO), NeoGenomics (NEO) and Wingstop (WING).

Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity

Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article.

Sanghamitra Saha headshot

5 Top Stocks Likely to Come Up With Earnings Beat

These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).

Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 60% and 6.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Predict a 41% Upside in NeoGenomics (NEO): Here's What You Should Know

The mean of analysts' price targets for NeoGenomics (NEO) points to a 40.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 26.32% and 5.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

ITeos Therapeutics, Inc. (ITOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Aug 10, 2022

Companies in The News Are: NEO,H,ARMK,AHCO

NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Lags Q4 Earnings Estimates

Techne (TECH) delivered earnings and revenue surprises of -0.49% and 0.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?

NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: NeoGenomics (NEO) Q1 Earnings Expected to Decline

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Illumina (ILMN) Debuts TSO Comprehensive Test in Europe

Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.

NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?